Results 21 to 30 of about 4,518,294 (325)

Natural AMPK Activators in Cardiovascular Disease Prevention

open access: yesFrontiers in Pharmacology, 2022
Cardiovascular diseases (CVD), as a life-threatening global disease, is receiving worldwide attention. Seeking novel therapeutic strategies and agents is of utmost importance to curb CVD.
Reza Heidary Moghaddam   +8 more
doaj   +1 more source

Diabetes: how to manage cardiovascular risk in secondary prevention patients

open access: yesDrugs in Context, 2022
Atherosclerotic cardiovascular disease (ASCVD) commonly affects people with type 2 diabetes (T2D). Historically, traditional cardiovascular (CV) risk-lowering therapies in patients with T2D and ASCVD have included antiplatelet agents, blood pressure ...
Sarah L Anderson, Joel C Marrs
doaj   +1 more source

Cardiovascular disease in type 2 diabetes mellitus: progress toward personalized management

open access: yesCardiovascular Diabetology, 2022
Cardiovascular diseases (CVDs) are the main cause of death among patients with type 2 diabetes mellitus (T2DM), particularly in low- and middle-income countries. To effectively prevent the development of CVDs in T2DM, considerable effort has been made to
Cheng-Xu Ma   +5 more
semanticscholar   +1 more source

Comprehensive Management of Cardiovascular Risk Factors for Adults With Type 2 Diabetes: A Scientific Statement From the American Heart Association

open access: yesCirculation, 2022
Cardiovascular disease remains the leading cause of death in patients with diabetes. Cardiovascular disease in diabetes is multifactorial, and control of the cardiovascular risk factors leads to substantial reductions in cardiovascular events.
Joshua J. Joseph   +8 more
semanticscholar   +1 more source

Nanomedicines for cardiovascular disease

open access: yesNature Cardiovascular Research, 2023
The leading cause of death in the world, cardiovascular disease (CVD), remains a formidable condition for researchers, clinicians and patients alike. CVD comprises a broad collection of diseases spanning the heart, the vasculature and the blood that runs
B. Smith, E. Edelman
semanticscholar   +1 more source

Cardiovascular Effects of an Immunosuppressive Agent Cyclosporin A [PDF]

open access: yesInternational Journal of Immunopathology and Pharmacology, 2002
Cyclosporin A (CsA) is now routinely used for transplantation of all solid organs, bone marrow transplantation, and for an increasing number of immunological diseases. However, treatment with CsA is an important iatrogenic cause of post-transplant hypertension, hyperlipidemia, and diabetes, which may contribute to the high cardiovascular morbidity in ...
H. Sakamoto, M. Kurabayashi
openaire   +3 more sources

Flavonoids as Natural Anti-Inflammatory Agents Targeting Nuclear Factor-Kappa B (NFκB) Signaling in Cardiovascular Diseases: A Mini Review

open access: yesFrontiers in Pharmacology, 2019
Cardiovascular diseases (CVDs) such as angina, hypertension, myocardial ischemia, and heart failure are the leading causes of morbidity and mortality worldwide. One of the major transcription factors widely associated with CVDs is nuclear factor-kappa B (
K. Choy   +5 more
semanticscholar   +1 more source

Comprehensive review of cardiovascular toxicity of drugs and related agents

open access: yesMedicinal research reviews (Print), 2018
Cardiovascular diseases are a leading cause of morbidity and mortality in most developed countries of the world. Pharmaceuticals, illicit drugs, and toxins can significantly contribute to the overall cardiovascular burden and thus deserve attention.
P. Mladěnka   +11 more
semanticscholar   +1 more source

Ranolazine: A true pluripotent cardiovascular drug or jack of all trades, master of none?

open access: yesSultan Qaboos University Medical Journal, 2018
Cardiovascular disease (CVD) is a leading cause of morbidity and mortality worldwide. Although the majority of patients with CVD are treated with interventional procedures, a substantial number require medical therapy in terms of both prognosis and ...
Alice Mezincescu   +2 more
doaj   +1 more source

Cardiovascular Effects of New Oral Glucose-Lowering Agents

open access: yesCirculation Research, 2018
Cardiovascular disease (CVD) is a major challenge in the management of type 2 diabetes mellitus. Glucose-lowering agents that reduce the risk of major cardiovascular events would be considered a major advance, as recently reported with liraglutide and ...
A. Scheen
semanticscholar   +1 more source

Home - About - Disclaimer - Privacy